A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
Hui Yang,1- 3 Shaoxing Sun,1- 3 Zijie Mei,1- 3 Qingming Xiang,1- 3 Chunxu Yang,1- 3 Min Chen,1- 3 Conghua Xie,1- 3 Yunfeng Zhou,1- 3 Hui Qiu1- 3 1Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China; 2Hubei Key Laboratory of Tumo...
Saved in:
Main Authors: | Yang H (Author), Sun S (Author), Mei Z (Author), Xiang Q (Author), Yang C (Author), Chen M (Author), Xie C (Author), Zhou Y (Author), Qiu H (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)
by: Szu-Ting Yang, et al.
Published: (2024) -
Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
by: Masafumi Yasunaga, et al.
Published: (2022) -
Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report
by: Jiwei Mao, et al.
Published: (2023) -
Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review
by: Yuke Wu, et al.
Published: (2024) -
Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line
by: Wang C, et al.
Published: (2023)